Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
Ralexar Therapeutics, Inc. See All Filings	D/A	2020-04-01 15:32:37 UTC
Amount To Be Raised $6,000,000 Associated Brokers / Dealers N/A CIK Number 0001596494 Filed Document 0001596494-20-000001 Exclusions or Exemptions 506b Accepted Date 2020-04-01 15:32:37 UTC Type of Offering D/A Industry Pharmaceuticals Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Ralexar Therapeutics, Inc. See All Filings	D	2019-01-04 09:48:09 UTC
Amount To Be Raised $6,000,000 Associated Brokers / Dealers N/A CIK Number 0001596494 Filed Document 0001596494-19-000002 Exclusions or Exemptions 506b Accepted Date 2019-01-04 09:48:09 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business PENNSYLVANIA Revenue or Assets Decline to Disclose Type of Security Equity
Ralexar Therapeutics, Inc. See All Filings	D	2017-06-08 09:25:33 UTC
Amount To Be Raised $6,908,638 Associated Brokers / Dealers N/A CIK Number 0001596494 Filed Document 0001596494-17-000002 Exclusions or Exemptions 506b Accepted Date 2017-06-08 09:25:33 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business PENNSYLVANIA Revenue or Assets Decline to Disclose Type of Security Equity
Alexar Therapeutics, Inc. See All Filings	D/A	2015-04-23 00:00:00 UTC
Amount To Be Raised $21,500,000 Associated Brokers / Dealers N/A CIK Number 0001596494 Filed Document 0001596494-15-000001 Exclusions or Exemptions 506b Accepted Date 2015-04-23 00:00:00 UTC Type of Offering D/A Industry Pharmaceuticals Principal Place of Business PENNSYLVANIA Revenue or Assets Decline to Disclose Type of Security Equity
Alexar Therapeutics, Inc. See All Filings	D	2014-01-07 00:00:00 UTC
Amount To Be Raised $21,500,000 Associated Brokers / Dealers N/A CIK Number 0001596494 Filed Document 0001596494-14-000001 Exclusions or Exemptions 506b Accepted Date 2014-01-07 00:00:00 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business PENNSYLVANIA Revenue or Assets Decline to Disclose Type of Security Equity